logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Combination of cediranib and olaparib has clinical benefit in BRCA wild-type platinum-resistant ovarian cancer

Small study shows encouraging results in heavily pretreated patients.